The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness
about
sameAs
Met in urological cancersRoles of c-Met and RON kinases in tumor progression and their potential as therapeutic targetsRon knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)Four individually druggable MET hotspots mediate HGF-driven tumor progression.Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications.Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration.Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues.The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapiesTumor-stroma interactionsTranscriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells.Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.Intron retention in the alternatively spliced region of RON results from weak 3' splice site recognition.RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer.Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.A distinct molecular profile associated with mucinous epithelial ovarian cancer.Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.Ovarian cancer biomarkers: a focus on genomic and proteomic findings.Prognostic significance of MST1R dysregulation in renal cell tumorsAn outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findingsKnockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines.Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasionMicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais.Met interacts with EGFR and Ron in canine osteosarcomaDifferential expression of RON in small and non-small cell lung cancers.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.Human airway trypsin-like protease, a serine protease involved in respiratory diseases.Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer.RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer.Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells.Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells.Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma.Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.Elevated RON protein expression in endometriosis and disease-associated ovarian cancers.
P2860
Q26864988-1DBDB8AA-5AC3-4E35-8374-BEEF12C6E948Q28081193-80A47F21-D92F-4BC9-9AE6-8B23A2DC277BQ28534954-5AA3A0DB-5B8A-48E3-8D93-7C941B7BE9CEQ30581656-EC9DF0B6-50CE-4F6B-8EA7-6419EC7C6BD5Q31099702-C2955799-0782-4EEE-84A1-95558063E97CQ33357902-6E9CEC36-D5DD-4224-9DCE-9C7F81EC710DQ33387952-EDEBA515-ED0F-44FF-907A-128159E5B78FQ33563635-AFF9F6A0-D588-42A7-8665-97600E124B4AQ33643964-8BFBE601-E44F-4401-B94B-8050D5E0A34EQ33874421-FA24DA86-5D20-4D51-B0B8-1A88DB7F634DQ33916081-B089710B-A651-479C-A9F3-F77BB81A40F7Q34042332-2711F616-A366-444E-B32E-F23AD63FFEDDQ34518350-CF824879-2B4B-4147-907A-9CF0C472FC0FQ35025393-D4F30454-29F6-40F9-A8CF-7B91ECFA3E09Q35146597-6FA5B75F-FB63-4FEA-B52B-106FF1B9C119Q35577352-E65E535B-A44D-4007-A5FD-E264C359F4D9Q35742089-5734C269-E6B1-434D-BB56-7642EFCE71FCQ36488410-E3982684-0602-4D94-99C1-59F5E4282715Q36520263-9CF07F34-A0F8-4AB6-B199-9F19E6C0EF08Q36614490-276D47C2-4607-4593-B762-98BC8FC48944Q36615866-DA9A9248-327D-4E89-B11C-C48FA9B54848Q37119992-856C0DD8-62FF-4366-A7F4-1E5E82672B0AQ37215552-A2CD1E5E-1E2C-4910-9E19-44ECC28E2C04Q37260040-184681B8-6199-4A6C-B91B-941917ADD719Q37275734-4BE4FD1E-7B92-407D-B659-B2CC0661FFFBQ37340100-DA8BC8DF-BEEB-4ACD-A48A-FD87EFA7478EQ37377252-F2F7B1CA-90FE-4319-A75D-DD0A3781DB6BQ37672081-447734A7-7F73-4A99-B378-8033DD0239FEQ38403475-40B295B6-1F4A-4043-8C16-E182C83D9EEFQ38922319-034C2FC0-C1F7-4189-984C-9F307C0A25FBQ38978586-884AFA16-FA2A-4313-9E86-CAAAC94DFD27Q39149977-D8696A95-A88A-428F-BA2B-DCEDB2D8012CQ39298765-2EBC3FC5-08B4-47C1-8EFC-EAD8BE7FE121Q39412662-918B2DF1-A23B-494E-81EA-023584B477AEQ39477514-232EE854-63D4-4A93-8CDE-F46EACF2D18DQ40029336-A5149500-5329-4E78-ADF7-B5F3766B25D9Q42837140-46520A33-FE03-4E2B-A462-77881BB2259AQ44718464-F99079B5-08FD-4753-A343-FE2884DFE8E9Q49887893-A580DB00-0BC7-4A02-AEBB-52C86D766C34Q51303205-5F9B3DEF-E3CD-4EC1-93A9-64434DB92A59
P2860
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The RON and MET oncogenes are ...... ate in activating invasiveness
@ast
The RON and MET oncogenes are ...... ate in activating invasiveness
@en
The RON and MET oncogenes are ...... ate in activating invasiveness
@nl
type
label
The RON and MET oncogenes are ...... ate in activating invasiveness
@ast
The RON and MET oncogenes are ...... ate in activating invasiveness
@en
The RON and MET oncogenes are ...... ate in activating invasiveness
@nl
prefLabel
The RON and MET oncogenes are ...... ate in activating invasiveness
@ast
The RON and MET oncogenes are ...... ate in activating invasiveness
@en
The RON and MET oncogenes are ...... ate in activating invasiveness
@nl
P2093
P3181
P1476
The RON and MET oncogenes are ...... ate in activating invasiveness
@en
P2093
Annalisa Lorenzato
Barbara Costa
Dionyssios Katsaros
Marco Massobrio
Massimo Castagnaro
Piera Maggiora
Riccardo Arisio
Stefano Fracchioli
P3181
P356
10.1016/S0014-4827(03)00250-7
P407
P577
2003-08-15T00:00:00Z